Twitter

Link your Twitter Account to Market Wire News


When you linking your Twitter Account Market Wire News Trending Stocks news and your Portfolio Stocks News will automatically tweet from your Twitter account.


Be alerted of any news about your stocks and see what other stocks are trending.


home / news releases / AUPH - Attractive Risk-Reward Profile For Hepion Pharmaceuticals

AUPH - Attractive Risk-Reward Profile For Hepion Pharmaceuticals

Aurinia Pharmaceuticals Inc
  • Hepion's leading candidate CRV431 may have the best anti-fibrotic effect among the numerous NASH candidates.
  • CRV431's analogs have been widely studied in various clinical trials, and were proven to be well-tolerated.
  • Hepion's management has extensive experience with cyclophilin inhibitors.
  • Given its tiny market cap of merely $95M, we think HEPA is an attractive investment target.

For further details see:

Attractive Risk-Reward Profile For Hepion Pharmaceuticals
Stock Information
Company Name: Aurinia Pharmaceuticals Inc
Stock Symbol: AUPH
Market: NASDAQ
Website: auriniapharma.com
Menu
AUPH AUPH Quote AUPH Short AUPH News AUPH Articles AUPH Message Board
Get AUPH Alerts

News, Short Squeeze, Breakout and More Instantly...